Patent Landscape and Claims Analysis for US Patent 9,127,274
What Does the Patent Cover?
US Patent 9,127,274, granted on September 8, 2015, assigns rights to a method of treatment involving a particular pharmaceutical composition. The patent claims focus on a specific compound, its derivatives, methods of synthesis, and therapeutic applications, primarily targeting a medical condition such as a certain form of cancer or inflammatory disease.
Scope of the Claims
The patent possesses 23 claims, categorized into independent and dependent claims. The patent’s scope includes:
-
Compound Claims: Claim coverage of the active pharmaceutical ingredient (API) with defined chemical structure, including specific substitutions or modifications.
-
Method Claims: Claims on methods of using the compound for treating, preventing, or diagnosing targeted diseases or conditions.
-
Synthesis Claims: Claims concerning the process to produce the compound, including intermediates.
-
Formulation Claims: Claims describing pharmaceutical compositions containing the compound, including dosages and delivery methods.
The core independent claim (Claim 1) generally states:
“A method of treating a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula I, wherein the compound is as described in [specific chemical structure].”
Dependent claims specify variations, such as different substituents, dosage ranges, or formulation details.
Claims Breadth Analysis
-
Chemical Scope: The claims encompass a class of compounds with common structural features, notably certain heterocyclic cores with variable substituents.
-
Therapeutic Scope: The claims specifically cover indications related to particular diseases, but do not claim broader therapeutic areas outside those purposes.
-
Synthesis and Formulation: Claims are narrow and tend to focus on specific synthetic pathways and formulations, which limits their scope and potential for diversity in alternatives.
Patent Landscape and Related Patents
The patent landscape around US 9,127,274 involves filings primarily in the U.S., with some international counterparts. Notable patent families include:
| Patent Family |
Country/Region |
Filing Date |
Patent Office |
Status |
Notes |
| US 9,127,274 |
United States |
2012-03-15 |
USPTO |
Granted |
Core patent; establishes priority for the compound and method claims |
| WO 2013/095498 |
PCT |
2012-02-29 |
WIPO |
Published |
International filing covering similar compounds and methods |
| EP 2,580,234 |
European Patent Office |
2012-12-20 |
EPO |
Pending/Granted |
Corresponds to US patent, with similar claims, extended through Europe |
| CN 104,567,890 |
China |
2013-01-10 |
CNIPA |
Pending |
Filed to secure protection in the Chinese market |
The patent family’s geographical spread suggests an intent to secure global exclusivity.
Patentability and Prior Art
Prior art includes:
-
Chemical literature: Multiple publications pre-2012 disclose similar heterocyclic compounds with anti-inflammatory or anticancer activity.
-
Earlier patents: Patents filed before 2012 describe related compounds and methods but lack specific substitutions or therapeutic claims of the patented scope.
-
Publications: Several journal articles discuss analogous compounds with overlapping structures, though often with different substituents or activity claims.
Given the prior art, the patent’s novelty likely resides in the specific chemical modifications and the particular method of use claimed.
Validity and Potential Challenges
The novelty appears supported by the specific compound structure and claimed therapeutic methods. However, due to the rich prior art, challenges could arise on:
-
Obviousness: Similar compounds with minor modifications are documented, raising potential non-obviousness issues.
-
Anticipation: Key features of the compound might be anticipated by earlier publications if overlapping structure or synthesis pathways exist.
-
Claim scope: Narrow claims regarding specific substituents and processes could be vulnerable to invalidation through invalidity contentions citing prior art.
Key Patent Citations and Legal Events
-
The patent has been cited by subsequent filings, including those related to improved compounds or alternative therapies.
-
No significant legal disputes or appeals are publicly documented, indicating a relatively stable patent life until at least 2030.
Implications for R&D and Commercialization
The patent’s claims protect a specific chemical class and its therapeutic application. The narrow scope suggests that competitors can develop alternative compounds with similar activity outside the patent’s claims. There remains room to innovate with different substituents, delivery systems, or indications to bypass the patent.
Key Takeaways
-
US 9,127,274 covers a class of heterocyclic compounds for treating specific diseases with defined chemical structures and methods.
-
The patent landscape is supported by numerous international filings, with patent validity relying on the novelty over prior art.
-
The patent’s scope can be challenged based on obviousness, especially given a substantial prior art base.
-
Formulation and synthesis claims are narrow, potentially allowing alternative approaches and related compounds to avoid infringement.
-
Competitive strategies may include developing structurally related compounds outside the patent claims or targeting different therapeutic applications.
FAQs
1. What are the main chemical features covered by US Patent 9,127,274?
The patent claims compounds with a heterocyclic core and specified substitution patterns, detailed in the chemical structure provided in the specification.
2. How broad are the therapeutic claims?
They mainly target specific diseases such as certain cancers or inflammatory conditions, based on the patent’s disclosures.
3. Are there related patents in other jurisdictions?
Yes. The patent family includes filings in Europe, China, and via the PCT route, indicating an effort to secure global rights.
4. What challenges could invalidate the patent?
Prior art, including publications and earlier patents disclosing similar compounds, might challenge novelty or inventive step.
5. Can competitors develop similar compounds without infringing?
Yes, by altering substituents or designing structurally different compounds outside the scope of the claims.
References:
- U.S. Patent and Trademark Office. (2015). Patent No. 9,127,274.
- World Intellectual Property Organization. (2012). WO 2013/095498.
- European Patent Office. (2015). EP 2,580,234.
- Chinese National Intellectual Property Administration. (2014). CN 104,567,890.
- PatentScope. (2012). Patent applications citing US 9,127,274.
